Hatano Kousei Hospital

The trials here

What the 3 trials at this site are about, from their registry records.

Conditions

• Alzheimer disease3 trials
• Schizophrenia1 trial

Phase

• Phase 33 trials

Status

• Recruiting3 trials

Lead sponsor

• Bristol-Myers Squibb2 trials
• Karuna Therapeutics, Inc., a Bristol Myers Squibb company1 trial

Running trials

• Recruiting

  A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer's Disease (ADAGIO-3)

  NCT06937229· Phase 3· Bristol-Myers Squibb· Source

  Contact: Sakai Yoshiro, Site 1301

• Recruiting

  A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)

  NCT07011732· Phase 3· Bristol-Myers Squibb· Source

  Contact: Sakai Yoshiro, Site 1301

• Recruiting

  A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

  NCT06585787· Phase 3· Karuna Therapeutics, Inc., a Bristol Myers Squibb company· Source

  Contact: Yoshiro Sakai, Site 7505

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Alzheimer disease3 recruiting
• Schizophrenia1 recruiting